Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
J Gastroenterol Hepatol. 2011 Jan;26(1):116-21. doi: 10.1111/j.1440-1746.2010.06441.x.
In animal models for acute liver injury, the administration of some angiogenic factors such as vascular endothelial growth factor (VEGF) and granulocyte-colony stimulating factor (G-CSF) are shown to reduce liver injury and improve liver proliferative capacity. The aim of the present study was to assess the role of angiogenic factors in fulminant hepatic failure (FHF).
Serum levels of nine angiogenic factors (angiopoietin-2, follistatin, G-CSF, hepatocyte growth factor [HGF], interleukin-8, leptin, platelet-derived growth factor [PDGF]-BB, platelet endothelial cell adhesion molecule-1 and VEGF) were measured using the Bio-Plex Protein Array System in 30 patients, 17 of whom were diagnosed with FHF, 13 with acute hepatitis (AH), and 20 controls.
Serum levels of PDGF-BB and VEGF were lower in FHF patients than AH patients and controls (PDGF-BB; 2050±1572 pg/mL vs 4521±2419 pg/mL vs 8506±5500 pg/mL, VEGF; 39±38 pg/mL vs 144±122 pg/mL vs 205±121 pg/mL). By using univariate logistic regression models, serum levels of PDGF-BB and VEGF were associated with poor outcomes. Serum PDGF-BB levels were strongly correlated with serum VEGF levels (r=0.70). Furthermore, serum PDGF-BB levels were significantly correlated with platelet counts (r=0.79), PT activity (r=0.37) and D.Bil/T.Bil ratio (r=0.50), while serum VEGF levels were significantly correlated with platelet counts (r=0.68) and PT activity (r=0.38).
We consider that serum levels of PDGF-BB and VEGF are worth investigating as biomarkers for predicting outcomes of FHF patients.
在急性肝损伤的动物模型中，给予血管内皮生长因子（VEGF）和粒细胞集落刺激因子（G-CSF）等一些血管生成因子可减轻肝损伤并提高肝增殖能力。本研究的目的是评估血管生成因子在暴发性肝衰竭（FHF）中的作用。
使用 Bio-Plex 蛋白分析系统检测 30 例患者（其中 17 例诊断为 FHF，13 例为急性肝炎[AH]）和 20 例对照者血清中的 9 种血管生成因子（血管生成素-2、卵泡抑素、G-CSF、肝细胞生长因子[HGF]、白细胞介素-8、瘦素、血小板衍生生长因子[PDGF]-BB、血小板内皮细胞黏附分子-1 和 VEGF）的水平。
FHF 患者血清 PDGF-BB 和 VEGF 水平低于 AH 患者和对照组（PDGF-BB：2050±1572 pg/mL 比 4521±2419 pg/mL 比 8506±5500 pg/mL，VEGF：39±38 pg/mL 比 144±122 pg/mL 比 205±121 pg/mL）。使用单变量逻辑回归模型，血清 PDGF-BB 和 VEGF 水平与不良结局相关。血清 PDGF-BB 水平与 VEGF 水平呈强相关（r=0.70）。此外，血清 PDGF-BB 水平与血小板计数显著相关（r=0.79）、PT 活性（r=0.37）和 D.Bil/T.Bil 比值（r=0.50），而血清 VEGF 水平与血小板计数显著相关（r=0.68）和 PT 活性（r=0.38）。
我们认为血清 PDGF-BB 和 VEGF 水平值得作为预测 FHF 患者结局的生物标志物进行研究。
